# chronic obstructive pulmonary disease (COPD) - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lung tissue
- Comparison or endpoint: COPD versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: 75cb1462dc859d10e673df1637d9bfb35fbfd41f53bda923e17881eee80cc2ef
- Response HTTP status: 200
- Prompt tokens: 71896
- Completion tokens: 53853
- Reasoning tokens: 24790
- Total tokens: 125749
- API requests reported: 4
- Elapsed seconds: 63.834
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 936.215
- Question handoff seconds: 951.58
- Final benchmark system: E2seq; file rank 1/5; original repeat 2; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The provided transcriptomic dataset compares lung tissue from patients with chronic obstructive pulmonary disease (COPD) against normal controls, comprising 100 differentially expressed genes (83 upregulated, 17 downregulated). Rather than representing isolated genetic alterations, these transcriptomic changes reveal four interconnected biological themes characteristic of advanced tissue remodeling and chronic airway inflammation in COPD:

1. **Extracellular Matrix (ECM) Remodeling and Structural Airway Dynamics:** Upregulation of key structural and fibrotic modulators, including *MACF1* ($\text{log}_2\text{FC} = 1.5574408, \text{FDR} = 4.0173328\times 10^{-7}$), *GREM1* ($\text{log}_2\text{FC} = 1.6518516, \text{FDR} = 0.0071604634$), *FGG* ($\text{log}_2\text{FC} = 1.7629709, \text{FDR} = 0.0053060516$), and TGF-$\beta$ superfamily antisense transcripts (*TGFB2-AS1*, *INHBA-AS1*), points to active tissue breakdown, alveolar wall destruction, and compensatory fibrotic repair in the diseased lung parenchymal microenvironment.
2. **Mucosal Innate Host Defense and Inflammatory Infiltration:** Heightened expression of mucosal immune effectors such as *DEFB1* ($\text{log}_2\text{FC} = 1.4043893, \text{FDR} = 0.0073663919$), *MGAM* ($\text{log}_2\text{FC} = 1.4865653, \text{FDR} = 0.0010724713$), and *CRACR2A* ($\text{log}_2\text{FC} = 1.0343014, \text{FDR} = 0.0003571688$), alongside B-cell immunoglobulin light chain components (*IGKV1-8*, $\text{log}_2\text{FC} = 1.8423925, \text{FDR} = 0.00085862227$), reflects ongoing bacterial/antigenic exposure, epithelial stress, and infiltration of adaptive immune cells into pulmonary tissues.
3. **Non-Coding RNA and Post-Transcriptional Network Expansion:** A dominant feature of this dataset is the widespread induction of non-coding RNA transcripts, including nuclear regulatory RNAs (*RN7SK*, $\text{log}_2\text{FC} = 1.7745113, \text{FDR} = 3.1335258\times 10^{-6}$), microRNAs (*MIR132*, $\text{log}_2\text{FC} = 1.646143, \text{FDR} = 0.00023723359$), and numerous antisense long non-coding RNAs (*CELF2-AS1*, *SNX29-AS3*, *LRP1-AS*). This indicates extensive post-transcriptional and epigenetic rewiring of gene expression networks in injured airway cells.
4. **Mitochondrial Bioenergetic and Translational Suppression:** Downregulation of mitochondrial respiratory genes (*UQCRBP1*, $\text{log}_2\text{FC} = -1.2048963, \text{FDR} = 3.1335258\times 10^{-6}$) and protein chaperone/ribosomal components (*NACA2*, *RPL23AP32*) highlights a decline in mitochondrial oxidative phosphorylation and translational sorting, consistent with metabolic stress and cellular senescence in COPD epithelium.

---

### 2. Core Biological Programs

```
COPD Lung Tissue Transcriptomic Architecture
 ├── Program 1: ECM Remodeling & Fibrotic Signaling (Upregulated: GREM1, FGG, MACF1, TGFB2-AS1)
 ├── Program 2: Mucosal Innate Defense & Immunity (Upregulated: DEFB1, IGKV1-8, MGAM, CRACR2A)
 ├── Program 3: Non-Coding RNA Transcriptional Control (Upregulated: RN7SK, MIR132, CELF2-AS1, SNX29-AS3)
 └── Program 4: Mitochondrial Bioenergetics & Proteostasis (Downregulated: UQCRBP1, NACA2, RPL23AP32)
```

#### Program 1: Extracellular Matrix Remodeling, Fibrin Deposition, and Fibrotic Signaling
* **Direction:** Upregulated
* **Major Supporting Genes:** *GREM1* ($\text{log}_2\text{FC} = 1.6518516, \text{FDR} = 0.0071604634$), *FGG* ($\text{log}_2\text{FC} = 1.7629709, \text{FDR} = 0.0053060516$), *MACF1* ($\text{log}_2\text{FC} = 1.5574408, \text{FDR} = 4.0173328\times 10^{-7}$), *TGFB2-AS1* ($\text{log}_2\text{FC} = 1.0385268, \text{FDR} = 0.0073663919$), *INHBA-AS1* ($\text{log}_2\text{FC} = 1.1892785, \text{FDR} = 0.013566699$).
* **Standardized Pathway:** Reactome: Extracellular Matrix Organization (R-HSA-1474290) / Hallmark: Epithelial Mesenchymal Transition.
* **Biological Explanation:** *GREM1* (Gremlin-1) acts as a antagonist of bone morphogenetic proteins (BMPs), promoting uninhibited TGF-$\beta$ signaling, myofibroblast differentiation, and extracellular matrix deposition in small airways. *FGG* (Fibrinogen gamma chain) indicates vascular hyperpermeability and fibrin scaffold deposition resulting from chronic microvascular damage. *MACF1* (Microtubule-actin crosslinking factor 1) coordinates cytoskeletal dynamics during epithelial migration and structural repair. Antisense RNAs *TGFB2-AS1* and *INHBA-AS1* suggest regulatory engagement of TGF-$\beta$/Activin ligand pathways.
* **Evidence Strength & Limitations:** Strong internal statistical support in the input dataset (all FDR $< 0.02$). **Major limitation:** External statistical validation was not performed in an independent test cohort; bulk tissue sequencing cannot distinguish whether matrix alterations stem from parenchymal fibroblasts, vascular cells, or airway epithelial cells.

#### Program 2: Mucosal Innate Defense and Inflammatory Host Response
* **Direction:** Upregulated
* **Major Supporting Genes:** *DEFB1* ($\text{log}_2\text{FC} = 1.4043893, \text{FDR} = 0.0073663919$), *IGKV1-8* ($\text{log}_2\text{FC} = 1.8423925, \text{FDR} = 0.00085862227$), *MGAM* ($\text{log}_2\text{FC} = 1.4865653, \text{FDR} = 0.0010724713$), *CRACR2A* ($\text{log}_2\text{FC} = 1.0343014, \text{FDR} = 0.0003571688$), *CLDN16* ($\text{log}_2\text{FC} = 1.6960274, \text{FDR} = 0.00038691539$).
* **Standardized Pathway:** GO:0090027 (Negative Regulation Of Monocyte Chemotaxis) / KEGG: Staphylococcus aureus infection (hsa05150) / Reactome: Neutrophil Degranulation (R-HSA-6798695).
* **Biological Explanation:** *DEFB1* (Defensin beta 1) is an antimicrobial peptide expressed by mucosal epithelia to combat bacterial colonization, which frequently complicates COPD. *IGKV1-8* reflects local infiltration of antibody-producing B cells/plasma cells forming tertiary lymphoid organs in chronic inflammation. *MGAM* participates in neutrophil degranulation and cell-surface carbohydrate catabolism. *CRACR2A* modulates calcium influx required for T-cell and innate immune cell activation. *CLDN16* regulates paracellular epithelial tight junction permeability.
* **Evidence Strength & Limitations:** High statistical significance in direct input data (FDR $< 0.008$). **Major limitation:** External statistical validation was not performed; increased *IGKV1-8* primarily reflects immune cell compositional shifts within diseased tissue biopsies rather than cell-intrinsic transcript induction.

#### Program 3: Non-Coding RNA and Post-Transcriptional Network Remodeling
* **Direction:** Upregulated
* **Major Supporting Genes:** *RN7SK* ($\text{log}_2\text{FC} = 1.7745113, \text{FDR} = 3.1335258\times 10^{-6}$), *MIR132* ($\text{log}_2\text{FC} = 1.646143, \text{FDR} = 0.00023723359$), *CELF2-AS1* ($\text{log}_2\text{FC} = 2.0550743, \text{FDR} = 1.0844164\times 10^{-8}$), *SNX29-AS3* ($\text{log}_2\text{FC} = 1.6777419, \text{FDR} = 1.0050992\times 10^{-9}$), *LRP1-AS* ($\text{log}_2\text{FC} = 1.2850607, \text{FDR} = 3.1335258\times 10^{-6}$).
* **Standardized Pathway:** Reactome: GATA6-AS1 lncRNA (R-HSA-9827615) / Non-Coding RNA Processing.
* **Biological Explanation:** *RN7SK* is a small nuclear RNA that sequesters positive transcription elongation factor b (P-TEFb), thereby exerting global control over RNA Polymerase II transcriptional elongation during cellular stress. *MIR132* regulates post-transcriptional inflammatory gene suppression. The extensive elevation of antisense lncRNAs (*CELF2-AS1*, *SNX29-AS3*, *LRP1-AS*) reflects broad non-coding activation that can regulate sense transcript splicing, stability, or nuclear chromatin remodeling.
* **Evidence Strength & Limitations:** Extremely low P-values and FDR across multiple independent non-coding transcripts. **Major limitation:** External statistical validation was not performed; functional mRNA targets for uncharacterized antisense RNAs (e.g., *SNX29-AS3*) cannot be conclusively identified without direct experimental perturbation.

#### Program 4: Mitochondrial Bioenergetic and Proteostatic Suppression
* **Direction:** Downregulated
* **Major Supporting Genes:** *UQCRBP1* ($\text{log}_2\text{FC} = -1.2048963, \text{FDR} = 3.1335258\times 10^{-6}$), *NACA2* ($\text{log}_2\text{FC} = -1.1533729, \text{FDR} = 0.00040222317$), *RPL23AP32* ($\text{log}_2\text{FC} = -1.6567379, \text{FDR} = 0.00013585145$), *RASSF7* ($\text{log}_2\text{FC} = -0.91092642, \text{FDR} = 0.0023891393$), *PTPRCAP* ($\text{log}_2\text{FC} = -0.87182811, \text{FDR} = 0.016796756$).
* **Standardized Pathway:** Reactome: Respiratory Electron Transport (R-HSA-611105) / Translation.
* **Biological Explanation:** Downregulation of *UQCRBP1* (ubiquinol-cytochrome c reductase complex member/pseudogene) suggests impaired electron transport chain function and mitochondrial dysfunction under chronic oxidative stress. Suppression of *NACA2* (nascent polypeptide-associated complex subunit alpha 2) and ribosomal-related pseudogenes (*RPL23AP32*) points to compromised translational folding, protein targeting, and proteostatic capacity in damaged parenchymal tissue.
* **Evidence Strength & Limitations:** Statistically robust in input dataset (all FDR $< 0.02$). **Major limitation:** External statistical validation was not performed; pseudogene quantification carries technical ambiguity due to potential sequence alignment overlap with parent functional genes.

---

### 3. Key Genes and Interaction Modules

| Gene Name | Effect Direction | $\text{log}_2\text{FC}$ | $P\text{-value}$ | FDR | Biological Function in Program | Explicit Interaction / Relationship Type |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **ETV3L** | Upregulated | 1.4722308 | $1.366\times 10^{-15}$ | $2.749\times 10^{-11}$ | ETS-domain transcription factor driving epithelial cell lineage commitment or cellular differentiation | **Regulatory interaction** (putative transcriptional regulation of downstream nuclear target networks) |
| **MACF1** | Upregulated | 1.5574408 | $7.982\times 10^{-11}$ | $4.017\times 10^{-7}$ | Spectraplakin crosslinking actin filaments to microtubules during epithelial motility and tissue repair | **Pathway co-membership** (co-associated with cytoskeletal dynamics and focal adhesion structural modules) |
| **GREM1** | Upregulated | 1.6518516 | $2.312\times 10^{-5}$ | 0.0071604634 | Antagonizes extracellular BMP ligands to permit TGF-$\beta$-driven airway fibrosis and matrix accumulation | **Regulatory interaction** (secreted paracrine antagonist of extracellular BMP2/4/7 protein signaling) |
| **DEFB1** | Upregulated | 1.4043893 | $2.563\times 10^{-5}$ | 0.0073663919 | Airway epithelial antimicrobial peptide protecting against chronic bacterial challenge | **Pathway co-membership** (member of mucosal innate host defense and epithelial barrier antimicrobial networks) |
| **FGG** | Upregulated | 1.7629709 | $1.634\times 10^{-5}$ | 0.0053060516 | Fibrinogen gamma subunit involved in microvascular clot formation and ECM provisional scaffold assembly | **Direct physical interaction** (binds FGA and FGB subunits to form the heterotrimeric fibrinogen protein complex) |
| **RN7SK** | Upregulated | 1.7745113 | $1.479\times 10^{-9}$ | $3.134\times 10^{-6}$ | Small nuclear RNA controlling transcriptional elongation via P-TEFb (CDK9/CCNT1) complex sequestration | **Direct physical interaction / Regulatory interaction** (binds HEXIM1 and LARP7 proteins to repress CDK9 kinase activity) |
| **MIR132** | Upregulated | 1.6461430 | $3.064\times 10^{-7}$ | 0.00023723359 | MicroRNA involved in post-transcriptional suppression of target mRNAs regulating immune responses | **Regulatory interaction** (binds $3'\text{-UTR}$ sequences of target mRNAs for translational repression or degradation) |
| **CLDN16** | Upregulated | 1.6960274 | $6.961\times 10^{-7}$ | 0.00038691539 | Claudin tight junction protein regulating paracellular ion permeability across airway epithelia | **Direct physical interaction** (assembles into homophilic/heterophilic intercellular tight junction complexes) |
| **UQCRBP1** | Downregulated | -1.2048963 | $1.556\times 10^{-9}$ | $3.134\times 10^{-6}$ | Mitochondrial respiratory complex III related gene reflecting oxidative energy failure | **Pathway co-membership** (co-functions with mitochondrial electron transport chain complex III assemblies) |
| **IGKV1-8** | Upregulated | 1.8423925 | $2.005\times 10^{-6}$ | 0.00085862227 | Immunoglobulin light chain variable region reflecting plasma cell expansion in tertiary lymphoid follicles | **Co-expression** (co-expressed with B-cell lineage markers reflecting immune cell tissue composition shifts) |

---

### 4. Validation Priorities

#### 1. GREM1-Mediated BMP Antagonism in Airway Remodeling
* **Classification:** Mechanistic hypothesis
* **Prioritization Rationale:** *GREM1* ($\text{log}_2\text{FC} = 1.6518516, \text{FDR} = 0.0071604634$) is an extracellular BMP antagonist. Dysregulated BMP/TGF-$\beta$ balance is a primary driver of subepithelial fibrosis in COPD.
* **Input Dataset Evidence:** Strong upregulation in diseased lung tissue ($P = 2.312\times 10^{-5}$).
* **External Evidence:** Published literature and pathway records confirm Gremlin-1 promotes epithelial-mesenchymal transition and extracellular matrix production; however, external statistical validation was not performed.
* **Recommended Next Step:** Treat 3D air-liquid interface (ALI) cultured primary human bronchial epithelial cells with recombinant GREM1 or anti-GREM1 neutralizing antibodies, measuring downstream SMAD1/5/8 versus SMAD2/3 phosphorylation and collagen synthesis.
* **Validation Status:** Supported hypothesis

#### 2. Cell-Type Deconvolution of IGKV1-8 and Adaptive Immune Infiltration
* **Classification:** Confounding or composition check
* **Prioritization Rationale:** High elevation of *IGKV1-8* ($\text{log}_2\text{FC} = 1.8423925, \text{FDR} = 0.00085862227$) could reflect an increased proportion of infiltrating B-cells/plasma cells rather than intrinsic cell transcriptional activation.
* **Input Dataset Evidence:** Significant elevation of immunoglobulin variable transcripts in bulk lung tissue.
* **External Evidence:** Human Protein Atlas (HPA) and GTEx confirm strict expression of *IGKV1-8* in B-lineage cells; external statistical validation was not performed.
* **Recommended Next Step:** Perform single-nucleus RNA sequencing (snRNA-seq) or multiplexed immunofluorescence (CD138, CD19, IgG) on COPD vs control tissue sections to quantify plasma cell density.
* **Validation Status:** Supported hypothesis

#### 3. RN7SK Control of Transcriptional Elongation in Injured Airway Epithelium
* **Classification:** Interaction / network hypothesis
* **Prioritization Rationale:** *RN7SK* ($\text{log}_2\text{FC} = 1.7745113, \text{FDR} = 3.1335258\times 10^{-6}$) is a master regulator of transcriptional elongation whose role in chronic respiratory stress remains incompletely understood.
* **Input Dataset Evidence:** Highly significant upregulation in COPD lung tissue ($P = 1.479\times 10^{-9}$).
* **External Evidence:** Reactome and biochemical literature establish RN7SK binding to the 7SK snRNP complex to inhibit P-TEFb (CDK9); external statistical validation was not performed.
* **Recommended Next Step:** RNA immunoprecipitation (RIP-qPCR) for CDK9 and precision run-on sequencing (PRO-seq) in human lung epithelial cells under oxidative stress to map RNA Pol II pausing dynamics.
* **Validation Status:** Exploratory hypothesis

#### 4. Sputum DEFB1 as a Non-Invasive Mucosal Biomarker
* **Classification:** Biomarker
* **Prioritization Rationale:** *DEFB1* ($\text{log}_2\text{FC} = 1.4043893, \text{FDR} = 0.0073663919$) encodes a secreted antimicrobial peptide accessible in lumenal airway fluids.
* **Input Dataset Evidence:** Increased expression in diseased tissue ($P = 2.563\times 10^{-5}$).
* **External Evidence:** QuickGO and UniProt document extracellular secretion of DEFB1 in mucosal surfaces; external statistical validation was not performed.
* **Recommended Next Step:** ELISA measurement of DEFB1 protein levels in sputum and bronchoalveolar lavage fluid (BALF) across COPD severity cohorts (GOLD stages I–IV) and non-COPD smokers.
* **Validation Status:** Exploratory hypothesis

#### 5. Anti-GREM1 Neutralization for Reversing Airway Remodeling
* **Classification:** Therapeutic target
* **Prioritization Rationale:** Neutralizing extracellular GREM1 could restore endogenous BMP signaling and halt progressive fibrotic wall thickening.
* **Input Dataset Evidence:** Marked elevation of *GREM1* in COPD tissue ($\text{log}_2\text{FC} = 1.6518516$).
* **External Evidence:** ChEMBL and Open Targets contain records for extracellular TGF-$\beta$/BMP pathway modulators, but the existence of target records does not establish clinical efficacy in COPD; external statistical validation was not performed.
* **Recommended Next Step:** Administer candidate anti-GREM1 monoclonal antibodies in cigarette smoke-exposed mouse models of chronic airway remodeling and measure lung compliance and airway wall thickness.
* **Validation Status:** Exploratory hypothesis

---

### 5. Evidence Grounding

The conclusions presented in this analysis are synthesized from multiple distinct evidence tiers:

```
Direct Input Cohort Statistics (The 100 DEGs with log2FC, P, FDR)
  └── Contextual Databases (GO, KEGG, Reactome, STRING, GTEx, HPA)
        └── Specific Literature Evidence (PMID 34814278, PMID 33996791)
              └── (Note: External Statistical Validation was NOT performed)
```

* **Direct Dataset Evidence:** Primary statistical metrics ($\text{log}_2\text{FC}$, $P\text{-value}$, FDR) derived from the user-provided table for 100 DEGs (83 upregulated, 17 downregulated) constitute the direct evidence for this cohort.
* **External Statistical Validation:** **External statistical validation was not performed.** No independent replication cohort statistics were provided to test the reproducibility of these 100 DEGs.
* **Pathway & Ontology Evidence:** Standardized GO terms (e.g., GO:0090027 negative regulation of monocyte chemotaxis) and Reactome records (e.g., R-HSA-1474290 ECM organization, R-HSA-9827615 GATA6-AS1 lncRNA) provide functional context. Note that databases such as QuickGO, KEGG, and Reactome rely on shared curated annotations and do not represent independent statistical replication.
* **Protein Interaction & Regulatory Networks:** STRING, TRRUST, and OmniPath records confirm known physical complexes (e.g., *FGG* heterotrimer assembly) and regulatory connections (*RN7SK* and P-TEFb).
* **Tissue & Cell Expression Evidence:** GTEx and Human Protein Atlas (HPA) profiles establish cell-type specificity (e.g., *IGKV1-8* restricted to plasma cells; *DEFB1* restricted to epithelia).
* **Therapeutic Target Evidence:** ChEMBL and ClinicalTrials records indicate drug-target interaction feasibility, but database presence alone is not evidence of therapeutic efficacy in COPD.
* **Published Literature Evidence:** Contextual literature records (e.g., PMID 34814278, PMID 33996791) support the plausibility of non-coding RNA and TGF-$\beta$ pathway involvement in pulmonary pathologies.
* **Evidence Conflicts & Insufficient Evidence:** While *DEFB1* transcript levels are elevated, chronic tobacco smoke exposure can functionally compromise defensin peptide activity via oxidation or proteolytic degradation; transcript elevation alone does not guarantee antimicrobial efficacy. Furthermore, functional downstream targets for novel antisense lncRNAs (*SNX29-AS3*, *CELF2-AS1*) lack direct lung-specific validation and are explicitly categorized as **insufficient evidence**.

---

### 6. Limitations and Alternative Explanations

1. **Tissue Heterogeneity and Cellular Composition Confounding:** Bulk lung tissue biopsies combine alveolar epithelial cells, bronchial epithelium, fibroblasts, vascular endothelial cells, and resident/infiltrating immune cells. Strong signals such as *IGKV1-8* ($\text{log}_2\text{FC} = 1.8423925$) or *MGAM* ($\text{log}_2\text{FC} = 1.4865653$) likely reflect an increased density of infiltrating plasma cells or neutrophils in COPD tissue rather than single-cell transcript induction. *Resolution:* Perform single-cell RNA sequencing (scRNA-seq) or digital cell-type deconvolution (e.g., CIBERSORTx) to isolate cell-type-specific differential expression.
2. **Absence of Independent Cohort Statistical Replication:** All statistical inferences are restricted to the provided single dataset of 100 DEGs. External statistical validation was not performed. *Resolution:* Re-evaluate the 100-gene transcriptomic signature across public independent COPD datasets (e.g., GEO / ArrayExpress cohorts).
3. **High Proportion of Non-Coding Transcripts and Pseudogenes:** Over 30% of the DEGs comprise lncRNAs, antisense transcripts (*CELF2-AS1*, *SNX29-AS3*), microRNAs (*MIR132*, *MIR3665*), or pseudogenes (*UQCRBP1*, *RPL23AP32*). Pseudogene mapping can suffer from sequence alignment artifacts, and functional annotations for many antisense RNAs remain uncharacterized. *Resolution:* Validate expression using strand-specific qRT-PCR and perform functional knockdown assays in primary human lung cells.
4. **Uncontrolled Clinical Covariates (Smoking, Disease Severity, Medication):** Bulk tissue profiles may be confounded by active cigarette smoking status, GOLD severity stage (I–IV), acute exacerbation status, or concurrent inhaled corticosteroid therapy, which alter inflammatory transcript levels independently of baseline COPD driver mechanisms. *Resolution:* Conduct multivariable regression modeling incorporating pack-years, medication history, and GOLD stage covariates.
5. **Association-versus-Causation Ambiguity:** Differentially expressed genes in end-stage or advanced COPD lung tissue may reflect secondary tissue injury, reactive inflammation, or compensatory repair rather than causal drivers of disease onset. *Resolution:* Perform Mendelian randomization integrating human lung eQTL datasets with large-scale COPD GWAS summary statistics to test causal directions.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 67/100 selected items (records returned); cbioportal 68/100 selected items (records returned); chembl 31/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 13/100 selected items (records returned); clinvar 68/100 selected items (records returned); ensembl 29/100 selected items (partially returned; some queries failed); europepmc 657 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 43/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 17/100 selected items (records returned); humanbase 89/100 selected items (partially returned; some queries failed); intact 20/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 9/100 selected items (records returned); opentargets 65/100 selected items (records returned); pubmed 254 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 22/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 23/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 4/100 selected items (records returned); string 19/100 selected items (records returned); trrust 2/100 selected items (records returned)
